Chattaraj Audrika, Freeman Amanda A, Nichols Kendall J, Ong Jason C, Plante David T, Saini Prabhjyot, Murray Catherine Friederich, King Rebecca, Bliwise Donald L, Trotti Lynn Marie
Emory University, Atlanta, GA, USA.
Center for the Study of Human Health, Emory University, Atlanta, GA, USA.
Sleep Med. 2025 Sep;133:106627. doi: 10.1016/j.sleep.2025.106627. Epub 2025 Jun 1.
Limited data are available regarding the long-term course of idiopathic hypersomnia. We analyzed longitudinal data from the Hypersomnia Foundation Registry at CoRDS to evaluate changes in symptoms and medication usage over time.
Registry participants reporting a diagnosis of idiopathic hypersomnia were included if they completed the registry questionnaire at least twice, with at least six months before first and last questionnaire. Responses were analyzed using paired t-test for continuous variables and McNemar test for categorical variables, comparing first and last responses.
Data from three hundred twenty-three participants were included, with a mean age 35.0 ± 12.2 and 86.5 % women. Average time between first and last response was 2.4 ± 1.4 years. Symptoms remained largely stable over the 2 ½ year period, with persistent difficulty awakening (in 78.7 % at baseline and 73.0 % at follow up), daytime sleepiness (62.7 % and 61.8 %), trouble waking up and functioning with normal alertness (56.4 % and 56.4 %), requiring multiple alarms (53.4 % and 55.3 %), brain fog (46.3 % and 48.4 %), and memory problems (42.7 % and 43.4 %). Average nightly sleep duration on workdays and non-workdays and average nap duration were all stable over time. Participants made an average of 0.8 ( ± 1.1) medication changes, with most (55.4 %) participants remaining on the same medications. Comorbid mood disorders were relatively common, with a modest increase in anxiety diagnoses.
Symptoms of idiopathic hypersomnia remained relatively stable over an average of 2.4 years of follow up. Despite persistent symptoms being experienced by the majority of participants, medication changes were infrequent.
关于特发性嗜睡症的长期病程,可用数据有限。我们分析了CoRDS的嗜睡症基金会登记处的纵向数据,以评估症状和药物使用随时间的变化。
如果登记参与者报告患有特发性嗜睡症诊断,并且至少完成两次登记调查问卷,且第一次和最后一次调查问卷之间至少间隔六个月,则将其纳入研究。对于连续变量,使用配对t检验分析回答;对于分类变量,使用McNemar检验分析回答,比较第一次和最后一次回答。
纳入了323名参与者的数据,平均年龄为35.0±12.2岁,女性占86.5%。第一次和最后一次回答之间的平均时间为2.4±1.4年。在2.5年的时间里,症状基本保持稳定,持续存在觉醒困难(基线时为78.7%,随访时为73.0%)、日间嗜睡(62.7%和61.8%)、醒来困难且难以正常清醒地运作(56.4%和56.4%)、需要多个闹钟(53.4%和55.3%)、脑雾(46.3%和48.4%)以及记忆问题(42.7%和43.4%)。工作日和非工作日的平均夜间睡眠时间以及平均午睡时间随时间均保持稳定。参与者平均进行了0.8(±1.1)次药物调整,大多数(55.4%)参与者仍使用相同的药物。共病情绪障碍相对常见,焦虑症诊断略有增加。
在平均2.4年的随访中,特发性嗜睡症的症状相对稳定。尽管大多数参与者持续出现症状,但药物调整并不频繁。